Les ventures K-Bio poursuivent le développement mondial de médicaments — entreprises et différenciateurs remarquables en 2021

RudaCure: Targeting diseases with high unmet needs to improve quality of life

RudaCure le PDG Yongho Kim spent 15 years conducting basic biomedical research on pain and troubles sensoriels at university while mentoring the next generation of chercheurs. Frustrated by the lack of commercialized technologies that could help patients, he founded his own entreprise biotechnologienologique and is now developing treatments covering the full spectrum of intractable troubles sensoriels with high unmet needs — from sécheresse oculaire to pain. [Related article: Developing treatments for 'troubles sensoriels' related to quality of life, from sécheresse oculaire to pain]

Actuellement, the traitement de la sécheresse oculaire candidate RCI001 is progressing at the fastest pace, with prévoit de faire progresser to essais cliniques de Phase 1 nationalally and internationally l'année prochaine. De plus, the traitement de la douleur RCI002, atopic dermatitis treatment RCI003, metastatic cancer treatment RCI004, and AMD/age-related macular degeneration treatment RCI005 are also under development.

메디게이트뉴스